Aptose to Hold Clinical Update and Data Review of AML Drug Tuspetinib on Sunday, December 11th
December 07, 2022 16:05 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Global Anti-Money Laundering (AML) Markets, 2021-2022 & 2027: Increasing Demand for More Consolidated Platforms - Major Players are ACI Worldwide, BAE Systems, Fiserv, and Oracle
December 07, 2022 06:33 ET
|
Research and Markets
Dublin, Dec. 07, 2022 (GLOBE NEWSWIRE) -- The "Anti-Money Laundering: Global Market Outlook" report has been added to ResearchAndMarkets.com's offering. The scope of the study includes anti-money...
Oncotelic Publishes SNO 27th Annual Meeting Presentation Materials
November 30, 2022 08:00 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a developer of treatments for rare and orphan indications,...
Aptose Treats First Patient with Continuous Dosing of New “G3” Formulation of Luxeptinib
November 14, 2022 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting...
GT Biopharma to Present New Data on Novel Dual-Antigen Targeting Approach Against AML at Upcoming 2022 ASH Annual Meeting
November 03, 2022 09:00 ET
|
GT Biopharma, Inc.
BRISBANE, CALIFORNIA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative...
Oncolyze, a Company Aiming to Treat Cancer by Exploding Cancer Cells, is Now Accepting Investments. Own a Piece in the Future of Cancer Treatment.
August 23, 2022 12:00 ET
|
Oncolyze Inc
NEW YORK, Aug. 23, 2022 (GLOBE NEWSWIRE) -- After successfully completing in vitro and in vivo (mice) experiments, which support the notion that its lead drug candidate OM-301 breaks down cancer...
Precipio Launches New 1-Step Technology for all HemeScreen Assays
August 16, 2022 11:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces the launch of its second generation of HemeScreen panels. Precipio’s...
Feedzai together with Lloyds Banking Group recognized as a Aite-Novarica Group 2022 Fraud Impact Award Winner
August 15, 2022 09:11 ET
|
Feedzai Inc
Feedzai’s RiskOps Platform recognized for their work with with Lloyds Banking Group in Best Transaction Fraud Monitoring and Decisioning Innovation categoryThe global award highlights how Feedzai’s...
Aite-Novarica Group Announces Winners of the 2022 Fraud & AML Impact Awards
August 15, 2022 08:00 ET
|
Aite-Novarica Group
Boston, MA, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Aite-Novarica Group is pleased to announce the winners of the 2022 Fraud & AML Impact Awards. The awards, which will be presented during...
Precipio to distribute HemeScreen® through Fisher Healthcare channel
July 20, 2022 10:30 ET
|
Precipio, Inc.
NEW HAVEN, Conn., July 20, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced that it has entered into an agreement with Fisher Healthcare,...